Estimated glomerular filtration rate with and without race for drug dosing: Cystatin C vs. serum creatinine

The goal of this study was to use a model kidney function clearance‐dependent drug (vancomycin) to understand the gain or loss of precision in dosing with use of serum creatinine (Scr), serum cystatin C (Scys) and race and nonrace‐based equations of the estimated glomerular filtration rate (eGFR). I...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2023-03, Vol.89 (3), p.1207-1210
Main Authors: Yun, Hyun Gi, Smith, Andrew J. F., DeBacker, Kenneth C., Pai, Manjunath P.
Format: Article
Language:English
Subjects:
Creatinine
creatinine clearance
Cystatin C
Glomerular Filtration Rate
Humans
Renal Insufficiency, Chronic
Vancomycin
vancomycin dosing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of this study was to use a model kidney function clearance‐dependent drug (vancomycin) to understand the gain or loss of precision in dosing with use of serum creatinine (Scr), serum cystatin C (Scys) and race and nonrace‐based equations of the estimated glomerular filtration rate (eGFR). In this study of hospitalized patients, we compared Scr, Scys and their combination to estimate kidney function and vancomycin clearance. The nonrace‐based Scys eGFR model outperformed other clearance models and improved the probability of target attainment by 15%. When Scys is not available, we show that the new 2021 CKD‐EPI eGFRcr equation (no race factor) performs as well as the current conventional approach. This improvement in model performance does not negate the need for individualized dosing but exemplifies the need to remove race as a factor of kidney‐function dose adjustment.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15592